Evidence map›Paper›PMID 34282773›Full record

ArticleCancers2021

A Novel Nanobody Precisely Visualizes Phosphorylated Histone H2AX in Living Cancer Cells under Drug-Induced Replication Stress.

Eric Moeglin, Dominique Desplancq, Audrey Stoessel, Christian Massute, Jeremy Ranniger, Alastair G McEwen, Gabrielle Zeder-Lutz, Mustapha Oulad-Abdelghani, Manuela Chiper, Pierre Lafaye and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Eric MoeglinBiotechnologie et Signalisation Cellulaire, UMR 7242, CNRS/Université de Strasbourg, Boulevard S. Brant, 67412 Illkirch, France.ORCID 0000-0001-9886-2247
Dominique DesplancqBiotechnologie et Signalisation Cellulaire, UMR 7242, CNRS/Université de Strasbourg, Boulevard S. Brant, 67412 Illkirch, France.
Audrey StoesselBiotechnologie et Signalisation Cellulaire, UMR 7242, CNRS/Université de Strasbourg, Boulevard S. Brant, 67412 Illkirch, France.
Christian MassuteSignaling Research Centers BIOSS and CIBSS and Institute of Biology II, University of Freiburg, Schänzlestrasse 1, 79104 Freiburg, Germany.
Jeremy RannigerSignaling Research Centers BIOSS and CIBSS and Institute of Biology II, University of Freiburg, Schänzlestrasse 1, 79104 Freiburg, Germany.
Alastair G McEwenInstitut de Génétique et de Biologie Moléculaire et Cellulaire Illkirch CEDEX, 67404 Illkirch, France.
Gabrielle Zeder-LutzBiotechnologie et Signalisation Cellulaire, UMR 7242, CNRS/Université de Strasbourg, Boulevard S. Brant, 67412 Illkirch, France.
Mustapha Oulad-AbdelghaniInstitut de Génétique et de Biologie Moléculaire et Cellulaire Illkirch CEDEX, 67404 Illkirch, France.ORCID 0000-0002-8381-4397
Manuela ChiperBiotechnologie et Signalisation Cellulaire, UMR 7242, CNRS/Université de Strasbourg, Boulevard S. Brant, 67412 Illkirch, France.ORCID 0000-0002-1563-5397
Pierre LafayePlateforme d'ingénierie des Anticorps, C2RT, UMR 3528, CNRS/Institut Pasteur, Rue du Dr. Roux, 75015 Paris, France.ORCID 0000-0002-5761-1342
Barbara Di VenturaSignaling Research Centers BIOSS and CIBSS and Institute of Biology II, University of Freiburg, Schänzlestrasse 1, 79104 Freiburg, Germany.
Pascal DidierLaboratoire de Bioimagerie et Pathologies, UMR 7021, Faculté de Pharmacie, CNRS/Université de Strasbourg, 74 Route du Rhin, 67401 Illkirch, France.
Arnaud PoterszmanInstitut de Génétique et de Biologie Moléculaire et Cellulaire Illkirch CEDEX, 67404 Illkirch, France.
Etienne WeissBiotechnologie et Signalisation Cellulaire, UMR 7242, CNRS/Université de Strasbourg, Boulevard S. Brant, 67412 Illkirch, France.ORCID 0000-0001-6622-6377
Centre National de la Recherche Scientifique · FRUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone H2AX phosphorylated at serine 139 (γ-H2AX) is a hallmark of DNA damage, signaling the presence of DNA double-strand breaks and global replication stress in mammalian cells. While γ-H2AX can be visualized with antibodies in fixed cells, its detection in living cells was so far not possible. Here, we used immune libraries and phage display to isolate nanobodies that specifically bind to γ-H2AX. We solved the crystal structure of the most soluble nanobody in complex with the phosphopeptide corresponding to the C-terminus of γ-H2AX and show the atomic constituents behind its specificity. We engineered a bivalent version of this nanobody and show that bivalency is essential to quantitatively visualize γ-H2AX in fixed drug-treated cells. After labelling with a chemical fluorophore, we were able to detect γ-H2AX in a single-step assay with the same sensitivity as with validated antibodies. Moreover, we produced fluorescent nanobody-dTomato fusion proteins and applied a transduction strategy to visualize with precision γ-H2AX foci present in intact living cells following drug treatment. Together, this novel tool allows performing fast screenings of genotoxic drugs and enables to study the dynamics of this particular chromatin modification in individual cancer cells under a variety of conditions.

Indexed as

cancer cellsgenotoxicity assay in live cellsH2AXimagingnanobodyone-step detectionphosphorylationreplication stress

Identifiers

PMID34282773
PMCPMC8267817
OpenAlexW3174817153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.